Loading…

Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells

Background Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (...

Full description

Saved in:
Bibliographic Details
Published in:Communications medicine 2024-09, Vol.4 (1), p.187-14, Article 187
Main Authors: Ishida, Masaaki, Masuda, Tomohiro, Sakai, Noriko, Nakai-Futatsugi, Yoko, Kamao, Hiroyuki, Shiina, Takashi, Takahashi, Masayo, Sugita, Sunao
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3
container_end_page 14
container_issue 1
container_start_page 187
container_title Communications medicine
container_volume 4
creator Ishida, Masaaki
Masuda, Tomohiro
Sakai, Noriko
Nakai-Futatsugi, Yoko
Kamao, Hiroyuki
Shiina, Takashi
Takahashi, Masayo
Sugita, Sunao
description Background Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II. Methods Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding class II MHC trans-activator ( CIITA ). Then the CIITA -knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male. Results Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment. Conclusions Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application. Plain language summary Transplantation of healthy cells can be used to treat irreversibly damaged organs. However, a concern is that the transplanted cells will be rejected by the immune system. Generally, the immune system protects our body when unknown materials invade. But this is undesirable during cell transplantation as the transplanted cells are often eliminated by the host’s immune cells. We demonstrated in monkeys that deletion of part of the immune system in cells prior to transplantation reduced the amount of immune system activity following transplantation. Using similar strategies in the future could enable cell transplants to be used more successfully in humans, making cell transplantation therapy safer and applicable to a wider number of patients. Ishida et al. transplant Crispr/Cas9 gene edited MHC-II knockout or wild-type retinal pigment epithelium into cynomolgus monkey eyes. MHC-II knockout RPE engraft successfully with no infiltration of inflammatory cells.
doi_str_mv 10.1038/s43856-024-00617-5
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_b0c88034134c424f9b2a5f55be3f201b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_b0c88034134c424f9b2a5f55be3f201b</doaj_id><sourcerecordid>3111635327</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3</originalsourceid><addsrcrecordid>eNp9kk1v1DAQhi0EotXSP8ABReLCJeDvOCeEKiiVKnFppR6QLNsZb71K4sVOVvTf4zSltBx6sj3zzjOeD4TeEvyRYKY-Zc6UkDWmvMZYkqYWL9AxbRiupeTXLx_dj9BJzjuMMW1kyxV-jY5Yy3grVHOMfp4l46cqz-kQDqavoq8Gs4upugl5ii4OezMFG_ow3VbLq4ffVQc-uABjCZtgqBz0fd1BCgfoqgRTGAtnMeY36JU3fYaT-3ODrr59vTz9Xl_8ODs__XJRO07pVDvTMcCulZwKUK6RrrHAObZeNZa3XdNiokB5RfDyYFJQSjuOO2uZcQrYBp2v3C6and6nMJh0q6MJ-s4Q01abNAXXg7bYKYUZJ4yX5Ny3lhrhhbDAPMXEFtbnlbWf7QCdK2Um0z-BPvWM4UZv40ETwjmVLSmED_eEFH_NkCc9hLz0w4wQ56wZIUQywcqANuj9f9JdnFPp36oqlRK-qOiqcinmnMA__IZgvSyDXpdBl2XQd8ugRQl697iOh5C_oy8CtgpycY1bSP9yP4P9AxNmwKM</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111365147</pqid></control><display><type>article</type><title>Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Springer Nature - nature.com Journals - Fully Open Access</source><creator>Ishida, Masaaki ; Masuda, Tomohiro ; Sakai, Noriko ; Nakai-Futatsugi, Yoko ; Kamao, Hiroyuki ; Shiina, Takashi ; Takahashi, Masayo ; Sugita, Sunao</creator><creatorcontrib>Ishida, Masaaki ; Masuda, Tomohiro ; Sakai, Noriko ; Nakai-Futatsugi, Yoko ; Kamao, Hiroyuki ; Shiina, Takashi ; Takahashi, Masayo ; Sugita, Sunao</creatorcontrib><description>Background Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II. Methods Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding class II MHC trans-activator ( CIITA ). Then the CIITA -knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male. Results Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment. Conclusions Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application. Plain language summary Transplantation of healthy cells can be used to treat irreversibly damaged organs. However, a concern is that the transplanted cells will be rejected by the immune system. Generally, the immune system protects our body when unknown materials invade. But this is undesirable during cell transplantation as the transplanted cells are often eliminated by the host’s immune cells. We demonstrated in monkeys that deletion of part of the immune system in cells prior to transplantation reduced the amount of immune system activity following transplantation. Using similar strategies in the future could enable cell transplants to be used more successfully in humans, making cell transplantation therapy safer and applicable to a wider number of patients. Ishida et al. transplant Crispr/Cas9 gene edited MHC-II knockout or wild-type retinal pigment epithelium into cynomolgus monkey eyes. MHC-II knockout RPE engraft successfully with no infiltration of inflammatory cells.</description><identifier>ISSN: 2730-664X</identifier><identifier>EISSN: 2730-664X</identifier><identifier>DOI: 10.1038/s43856-024-00617-5</identifier><identifier>PMID: 39349587</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>13 ; 13/107 ; 631/250/1854/2812 ; 631/532/489 ; Antibodies ; Antigens ; Cell culture ; Immunohistochemistry ; Laboratory animals ; Macular degeneration ; Medicine ; Medicine &amp; Public Health ; Stem cells ; Transplants &amp; implants</subject><ispartof>Communications medicine, 2024-09, Vol.4 (1), p.187-14, Article 187</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><rights>The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3</cites><orcidid>0000-0003-4187-6060 ; 0000-0002-2067-6708</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3111365147/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3111365147?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39349587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ishida, Masaaki</creatorcontrib><creatorcontrib>Masuda, Tomohiro</creatorcontrib><creatorcontrib>Sakai, Noriko</creatorcontrib><creatorcontrib>Nakai-Futatsugi, Yoko</creatorcontrib><creatorcontrib>Kamao, Hiroyuki</creatorcontrib><creatorcontrib>Shiina, Takashi</creatorcontrib><creatorcontrib>Takahashi, Masayo</creatorcontrib><creatorcontrib>Sugita, Sunao</creatorcontrib><title>Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells</title><title>Communications medicine</title><addtitle>Commun Med</addtitle><addtitle>Commun Med (Lond)</addtitle><description>Background Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II. Methods Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding class II MHC trans-activator ( CIITA ). Then the CIITA -knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male. Results Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment. Conclusions Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application. Plain language summary Transplantation of healthy cells can be used to treat irreversibly damaged organs. However, a concern is that the transplanted cells will be rejected by the immune system. Generally, the immune system protects our body when unknown materials invade. But this is undesirable during cell transplantation as the transplanted cells are often eliminated by the host’s immune cells. We demonstrated in monkeys that deletion of part of the immune system in cells prior to transplantation reduced the amount of immune system activity following transplantation. Using similar strategies in the future could enable cell transplants to be used more successfully in humans, making cell transplantation therapy safer and applicable to a wider number of patients. Ishida et al. transplant Crispr/Cas9 gene edited MHC-II knockout or wild-type retinal pigment epithelium into cynomolgus monkey eyes. MHC-II knockout RPE engraft successfully with no infiltration of inflammatory cells.</description><subject>13</subject><subject>13/107</subject><subject>631/250/1854/2812</subject><subject>631/532/489</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Cell culture</subject><subject>Immunohistochemistry</subject><subject>Laboratory animals</subject><subject>Macular degeneration</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Stem cells</subject><subject>Transplants &amp; implants</subject><issn>2730-664X</issn><issn>2730-664X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kk1v1DAQhi0EotXSP8ABReLCJeDvOCeEKiiVKnFppR6QLNsZb71K4sVOVvTf4zSltBx6sj3zzjOeD4TeEvyRYKY-Zc6UkDWmvMZYkqYWL9AxbRiupeTXLx_dj9BJzjuMMW1kyxV-jY5Yy3grVHOMfp4l46cqz-kQDqavoq8Gs4upugl5ii4OezMFG_ow3VbLq4ffVQc-uABjCZtgqBz0fd1BCgfoqgRTGAtnMeY36JU3fYaT-3ODrr59vTz9Xl_8ODs__XJRO07pVDvTMcCulZwKUK6RrrHAObZeNZa3XdNiokB5RfDyYFJQSjuOO2uZcQrYBp2v3C6and6nMJh0q6MJ-s4Q01abNAXXg7bYKYUZJ4yX5Ny3lhrhhbDAPMXEFtbnlbWf7QCdK2Um0z-BPvWM4UZv40ETwjmVLSmED_eEFH_NkCc9hLz0w4wQ56wZIUQywcqANuj9f9JdnFPp36oqlRK-qOiqcinmnMA__IZgvSyDXpdBl2XQd8ugRQl697iOh5C_oy8CtgpycY1bSP9yP4P9AxNmwKM</recordid><startdate>20240930</startdate><enddate>20240930</enddate><creator>Ishida, Masaaki</creator><creator>Masuda, Tomohiro</creator><creator>Sakai, Noriko</creator><creator>Nakai-Futatsugi, Yoko</creator><creator>Kamao, Hiroyuki</creator><creator>Shiina, Takashi</creator><creator>Takahashi, Masayo</creator><creator>Sugita, Sunao</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Portfolio</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-4187-6060</orcidid><orcidid>https://orcid.org/0000-0002-2067-6708</orcidid></search><sort><creationdate>20240930</creationdate><title>Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells</title><author>Ishida, Masaaki ; Masuda, Tomohiro ; Sakai, Noriko ; Nakai-Futatsugi, Yoko ; Kamao, Hiroyuki ; Shiina, Takashi ; Takahashi, Masayo ; Sugita, Sunao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>13</topic><topic>13/107</topic><topic>631/250/1854/2812</topic><topic>631/532/489</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Cell culture</topic><topic>Immunohistochemistry</topic><topic>Laboratory animals</topic><topic>Macular degeneration</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Stem cells</topic><topic>Transplants &amp; implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ishida, Masaaki</creatorcontrib><creatorcontrib>Masuda, Tomohiro</creatorcontrib><creatorcontrib>Sakai, Noriko</creatorcontrib><creatorcontrib>Nakai-Futatsugi, Yoko</creatorcontrib><creatorcontrib>Kamao, Hiroyuki</creatorcontrib><creatorcontrib>Shiina, Takashi</creatorcontrib><creatorcontrib>Takahashi, Masayo</creatorcontrib><creatorcontrib>Sugita, Sunao</creatorcontrib><collection>SpringerOpen</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medicine (ProQuest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database (ProQuest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Health Management Database (ProQuest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Communications medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ishida, Masaaki</au><au>Masuda, Tomohiro</au><au>Sakai, Noriko</au><au>Nakai-Futatsugi, Yoko</au><au>Kamao, Hiroyuki</au><au>Shiina, Takashi</au><au>Takahashi, Masayo</au><au>Sugita, Sunao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells</atitle><jtitle>Communications medicine</jtitle><stitle>Commun Med</stitle><addtitle>Commun Med (Lond)</addtitle><date>2024-09-30</date><risdate>2024</risdate><volume>4</volume><issue>1</issue><spage>187</spage><epage>14</epage><pages>187-14</pages><artnum>187</artnum><issn>2730-664X</issn><eissn>2730-664X</eissn><abstract>Background Gene editing of immunomodulating molecules is a potential transplantation strategy to control immune rejection. As we noticed the successful transplantation of retinal pigment epithelium (RPE) derived from embryonic stem cells of a cynomolgus monkey that accidentally lacked MHC class II (MHC-II) molecules, we hypothesized immune rejection could be evaded by suppressing MHC-II. Methods Gene editing by the Crispr/Cas9 system was performed in induced pluripotent stem cells derived from a cynomolgus monkey (miPSCs) for targeted deletion of the gene coding class II MHC trans-activator ( CIITA ). Then the CIITA -knocked out miPSCs were differentiated into RPE cells to generate miPSC-derived MHC-II knockout RPE. The MHC-II knockout or wild-type RPEs were transplanted into the eyes of healthy cynomolgus monkeys. All monkeys used in this study were male. Results Here we show when MHC-II knockout RPE are transplanted into monkey eyes, they show suppressed immunogenicity with no infiltration of inflammatory cells, leading to successful engraftment. Conclusions Our results reasonably evidence the efficacy of MHC-II knockout iPSC-RPE transplants for clinical application. Plain language summary Transplantation of healthy cells can be used to treat irreversibly damaged organs. However, a concern is that the transplanted cells will be rejected by the immune system. Generally, the immune system protects our body when unknown materials invade. But this is undesirable during cell transplantation as the transplanted cells are often eliminated by the host’s immune cells. We demonstrated in monkeys that deletion of part of the immune system in cells prior to transplantation reduced the amount of immune system activity following transplantation. Using similar strategies in the future could enable cell transplants to be used more successfully in humans, making cell transplantation therapy safer and applicable to a wider number of patients. Ishida et al. transplant Crispr/Cas9 gene edited MHC-II knockout or wild-type retinal pigment epithelium into cynomolgus monkey eyes. MHC-II knockout RPE engraft successfully with no infiltration of inflammatory cells.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>39349587</pmid><doi>10.1038/s43856-024-00617-5</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-4187-6060</orcidid><orcidid>https://orcid.org/0000-0002-2067-6708</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2730-664X
ispartof Communications medicine, 2024-09, Vol.4 (1), p.187-14, Article 187
issn 2730-664X
2730-664X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_b0c88034134c424f9b2a5f55be3f201b
source Publicly Available Content Database; PubMed Central; Alma/SFX Local Collection; Springer Nature - nature.com Journals - Fully Open Access
subjects 13
13/107
631/250/1854/2812
631/532/489
Antibodies
Antigens
Cell culture
Immunohistochemistry
Laboratory animals
Macular degeneration
Medicine
Medicine & Public Health
Stem cells
Transplants & implants
title Graft survival of major histocompatibility complex deficient stem cell-derived retinal cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A05%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Graft%20survival%20of%20major%20histocompatibility%20complex%20deficient%20stem%20cell-derived%20retinal%20cells&rft.jtitle=Communications%20medicine&rft.au=Ishida,%20Masaaki&rft.date=2024-09-30&rft.volume=4&rft.issue=1&rft.spage=187&rft.epage=14&rft.pages=187-14&rft.artnum=187&rft.issn=2730-664X&rft.eissn=2730-664X&rft_id=info:doi/10.1038/s43856-024-00617-5&rft_dat=%3Cproquest_doaj_%3E3111635327%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-cad3e0c96425e8c76c7be440bf87b49d79018e8f8109d79365222d40dbb3ac8e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3111365147&rft_id=info:pmid/39349587&rfr_iscdi=true